卡培他滨联合顺铂治疗耐药晚期三阴性乳腺癌的临床观察

Capecitabine combined with cisplatin in the treatment of drug-resistant advanced triple negative breast cancer

目的：探讨卡培他滨联合顺铂治疗蒽环类及紫杉类耐药的晚期三阴性乳腺癌的临床疗效。方法：22例蒽环类及紫杉类耐药的晚期三阴性乳腺癌患者，给予卡培他滨1000mg／m^2口服，2／d，d1～14；顺铂25mg／m^2，静脉滴注，1／d，d1～3。21d为1个化疗周期，所有患者均治疗2个周期以上，观察临床疗效及毒副反应。结果：CR1例，PR6例，SD12例，PD3例，总有效率为31．81％（7／22）。中位疾病进展时间（TTP）5．6个月（3～11个月）。主要的毒性反应有骨髓抑制、乏力、胃肠道反应及手足综合征等，为可逆性，无治疗相关死亡。结论：卡培他滨联合顺铂近期疗效较好，毒性反应可耐受，可作为蒽环类及紫杉类耐药的晚期三阴性乳腺癌患者的治疗选择。

Objective：To evaluate the efficacy and toxicity of combination chemotherapy of cisplatin and capecitabine for anthracycline-- and taxane--resistant advanced triple negative breast cancer （TNBC）. Methods： Twenty--two cases of antbracycline-- and taxane--resistant advanced TNBC received oral capecitabine （1000 mg/m2 ,twice a day, day 1--14） and intravenous cisplatin （25 mg/m2 , day 1--3）. The treatment was repeated every 21 days, and all patients received at least 2 cycles of chemotherapy. Results： CR was found in 1 patient, PR in 6, SD in 12, and PD in 3. The total effective rate was 31.81~ （7/22）. The median time to disease progression was 5.6 months. The major toxic reactions were reversible myelo- suppression, fatigue, gastrointestinal reaction and hand--foot syndrome. There was no treatment--related death. Conclusion： Combination therapy of capecitabine and cisplatin is an effective and well tolerated regi- men for anthracycline-- and taxane--resistant advanced TNBC patients.